L-363(人多發(fā)性骨髓瘤細(xì)胞)
CBP60240
                       
                         詢  價(jià)
                        
                        
                索取STR
                        
                    產(chǎn)品描述
                    產(chǎn)品數(shù)據(jù)庫(kù)
                    
                | I. General information | |
| Synonyms: | L-363 | 
| Background: | established from the peripheral blood of a 36-year-old woman with plasma cell leukemia (IgG) in 1977; cells were described in the literature to be EBNA-negative and to express mRNA for proto-oncogene BCL2; plasma cell leukemia is related to multiple myeloma | 
| Species: | human (Homo sapiens) | 
| Tissue: | N/A | 
| Disease: | plasma cell leukemia | 
| Gender: | N/A | 
| Morphology: | single, large, round or oval cells in suspension; | 
| Growth Mode: | N/A | 
| Doubling Time: | ca. 25 hours | 
| DNA Profile: | N/A Our Cell Line Authentication Service  | 
		
| Culture Medium: | 
				 RPMI-1640+10%FBS L-363完全培養(yǎng)基,# CBP60240M  | 
		
| Cryopreservation medium: | 90%FBS+10%DMSO | 
| Mycoplasma: | contamination was eliminated with Ciprobay (ciprofloxacin), then negative in DAPI, microbiological culture, RNA hybridization, PCR assays | 
| Immunology: | CD3 -, CD10 -, CD13 -, CD19 -, CD20 -, CD34 -, CD37 -, cyCD79a -, CD80 -, CD138 +, HLA-DR +, sm/cyIgG -, sm/cyIgM -, sm/cykappa -, sm/cylambda -; image | 
| Fingerprint: | multiplex PCR of minisatellite markers revealed a unique DNA profile | 
| Species: | confirmed as human with IEF of AST, LDH, PEP B | 
| Cytogenetics: | human hyperdiploid karyotype with 11% polyploidy - 49(45-50)<2n>X, -X, -X, -6, +7, +8, +11, +11, +14, +19, -22, t(5;8)(q12/13;q24.32), der(8)(t(5;8)(q12/13;q24.32), der(8)t(7;8)(q11.2;p22), del(11)(q13)x2, add(14)(q32), del(17)(p12), add(19)(q13) - sideline with add(13)(q34) - 11q13 and 14q32 breakpoints recurrent in PCL - resembles published karyotype | 
| Virus | ELISA: reverse transcriptase negative; PCR: EBV -, HBV -, HCV -, HHV-8 -, HIV-1 -, HIV-2 -, HTLV-I/II -, MLV -, SMRV - | 
| Comments: | For more information, please contact us (4008-750-250). |